LGC launches cGMP cell-based assay capability

LGC is delighted to launch cGMP cell-based assay capability, adding to the long-established drug development services delivered from its Fordham, Cambridgeshire, site.

This cGMP service is an extension to the existing cell-based assay capability that LGC’s experienced team offer for biopharmaceutical development.  LGC’s expertise spans a wide range of drug formulations and therapeutic areas and provides a comprehensive development service from discovery through to finished product.  This addition will enhance and complement LGC’s broad portfolio of CMC analytical capabilities ranging from method development and validation to batch release and stability assessment.   

Dr Andrew Roberts, Chief Scientist of the Biologicals team at LGC said, “We are delighted to be able to offer this new service to cGMP regulatory guidelines. This further extends our portfolio of GxP regulated cell-based assay that includes drug potency, immunogenicity and biomarkers.”

Through the acquisition of the leading bioanalytical business from Quotient Bioresearch in December 2012, LGC has a world-class bioanalytical capability with more than 50 years’ experience in high-integrity analytical science and expertise spanning small and large molecules, biomarkers, molecular biology and microbiology. LGC’s flexible and tailored services follow the same rigorous principles for all experimental work, reassuring all clients, whether requiring non-regulated discovery or full regulatory studies.